The first patient has been dosed in Telix Pharmaceuticals' carbonic anhydrase-(CAIX)-targeting PET/CT imaging agent TLX250-CDx (zirconium-89 DFO-girentuximab) trial.
The phase II trial, called Starburst, is intended to investigate the diagnostic and therapeutic efficacy of the agent for a variety of cancers, including breast, cervix, colorectal, gastric, esophageal, head and neck, lung, ovarian, pancreatic, and vulval, according to the firm.
